|
1
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Geest LG, Lam-Boer J, Koopman M,
Verhoef C, Elferink MA and de Wilt JH: Nationwide trends in
incidence, treatment and survival of colorectal cancer patients
with synchronous metastases. Clin Exp Metastasis. 32:457–465. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watanabe T, Itabashi M, Shimada Y, Tanaka
S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, et
al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2014 for treatment of colorectal cancer. Int J Clin
Oncol. 20:207–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fedewa SA, Ma J, Sauer AG, Siegel RL,
Smith RA, Wender RC, Doroshenk MK, Brawley OW, Ward EM and Jemal A:
How many individuals will need to be screened to increase
colorectal cancer screening prevalence to 80% by 2018? Cancer.
121:4258–4265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 (Suppl):iii1–iii9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lucero CM, Vega OA, Osorio MM, Tapia JC,
Antonelli M, Stein GS, van Wijnen AJ and Galindo MA: The
cancer-related transcription factor Runx2 modulates cell
proliferation in human osteosarcoma cell lines. J Cell Physiol.
228:714–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leong DT, Lim J, Goh X, Pratap J, Pereira
BP, Kwok HS, Nathan SS, Dobson JR, Lian JB, Ito Y, et al:
Cancer-related ectopic expression of the bone-related transcription
factor RUNX2 in non-osseous metastatic tumor cells is linked to
cell proliferation and motility. Breast Cancer Res. 12:R892010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chimge NO, Baniwal SK, Luo J, Coetzee S,
Khalid O, Berman BP, Tripathy D, Ellis MJ and Frenkel B: Opposing
effects of Runx2 and estradiol on breast cancer cell proliferation:
In vitro identification of reciprocally-regulated gene signature
related to clinical letrozole responsiveness. Clin Cancer Res.
18:901–911. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taipaleenmäki H, Browne G, Akech J, Zustin
J, van Wijnen AJ, Stein JL, Hesse E, Stein GS and Lian JB:
Targeting of Runx2 by miR-135 and miR-203 impairs progression of
breast cancer and metastatic bone disease. Cancer Res.
75:1433–1444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Colden M, Dar A, Saini S, Dahiya PV,
Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S:
MicroRNA-466 inhibits tumor growth and bone metastasis in prostate
cancer by direct regulation of osteogenic transcription factor
RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luo L, Tang H, Ling L, Li N, Jia X, Zhang
Z, Wang X, Shi L, Yin J, Qiu N, et al: LINC01638 lncRNA activates
MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation
in triple-negative breast cancer. Oncogene. 37:6166–6179. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCq method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xue Y, Ma G, Gu D, Zhu L, Hua Q, Du M, Chu
H, Tong N, Chen J, Zhang Z and Wang M: Genome-wide analysis of long
noncoding RNA signature in human colorectal cancer. Gene.
556:227–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wu H, Wu R, Chen M, Li D, Dai J, Zhang Y,
Gao K, Yu J, Hu G, Guo Y, et al: Comprehensive analysis of
differentially expressed profiles of lncRNAs and construction of
miR-133b mediated ceRNA network in colorectal cancer. Oncotarget.
8:21095–21105. 2017.PubMed/NCBI
|
|
16
|
Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao
X, Zhu W, Zhang X, Cheng Y, Ou K, et al: Circulating lncRNAs
associated with occurrence of colorectal cancer progression. Am J
Cancer Res. 5:2258–2265. 2015.PubMed/NCBI
|
|
17
|
Pratap J, Imbalzano KM, Underwood JM,
Cohet N, Gokul K, Akech J, van Wijnen AJ, Stein JL, Imbalzano AN,
Nickerson JA, et al: Ectopic runx2 expression in mammary epithelial
cells disrupts formation of normal acini structure: Implications
for breast cancer progression. Cancer Res. 69:6807–6814. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Akech J, Wixted J, Bedard K, van der Deen
M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR,
Altieri DC, et al: Runx2 association with progression of prostate
cancer in patients: Mechanisms mediating bone osteolysis and
osteoblastic metastatic lesions. Oncogene. 29:811–821. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu W, Qiao Y, Tang X, Ma L, Wang Y, Zhang
X, Weng W, Pan Q, Yu Y, Sun F and Wang J: Tumor suppressor long
non-coding RNA, MT1DP is negatively regulated by YAP and Runx2 to
inhibit FoxA1 in liver cancer cells. Cell Signal. 26:2961–2968.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu L and Xu PC: Downregulated LncRNA-ANCR
promotes osteoblast differentiation by targeting EZH2 and
regulating Runx2 expression. Biochem Biophys Res Commun.
432:612–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zidan HE, Karam RA, El-Seifi OS and Abd
Elrahman TM: Circulating long non-coding RNA MALAT1 expression as
molecular biomarker in egyptian patients with breast cancer. Cancer
Genet. 220:32–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
